Table 1 Patient demographics and baseline characteristics

Age (year)

55.0 ± 11.0

53.0 ± 9.0

57.0 ± 12.0

Sex

Male

80 (90.9%)

36 (85.7%)

44 (95.7%)

Female

8 (9.1%)

6 (14.3%)

2 (4.3%)

Child-Pugh classification

A

79 (89.8%)

38 (90.5%)

41 (89.1%)

B

9 (10.2%)

4 (9.5%)

5 (10.9%)

Tumor diameter (cm)

< 5 cm

63 (71.6%)

28 (66.7%)

35 (76.1%)

≥ 5 cm

25 (28.4%)

14 (33.3%)

11 (23.9%)

No. of tumors

< 3

59 (67.0%)

26 (61.9%)

33 (71.7%)

≥ 3

29 (33.0%)

16 (38.1%)

13 (28.3%)

Extrahepatic metastasis

Yes

63 (71.6%)

31 (73.8%)

32 (69.6%)

No

25 (28.4%)

11 (26.2%)

14 (30.4%)

Portal vein

tumor thrombus

No

78 (88.6%)

38 (90.5%)

40 (87.0%)

Yes

10 (11.4%)

4 (9.5%)

6 (13.0%)

AFP level (ng/mL)

≥ 400

32 (36.4%)

15 (35.7%)

17 (37.0%)

< 400

56 (63.6%)

27 (64.3%)

29 (63.0%)

MVI

Positive

47 (53.4%)

23 (54.8%)

24 (52.2%)

Negative

41 (46.6%)

19 (45.2%)

22 (47.8%)

Interval of recurrence from initial treatment

≥ 1 year

23 (26.1%)

12 (28.6%)

11 (23.9%)

<1 year

65 (73.9%)

30 (71.4%)

35 (76.1%)

ALT level (U/L)

28.0 (19.0, 41.0)

27.0 (18.0, 37.0)

29.0 (19.0, 56.0)

AST level (U/L)

30.0 (19.0, 45.0)

29.0 (20.0, 38.0)

32.0 (19.0, 55.0)

GGT level (U/L)

60.0 (37.0, 110.0)

62.0 (38.0, 105.0)

58.0 (36.0, 118.0)

Total bilirubin level (mg/dL)

14.0 (11.0, 19.0)

14.0 (10.0, 20.0)

14.0 (11.0, 19.0)

ALB level (g/L)

41.1 (38.4, 45.0)

41.2 (38.5, 43.4)

41.0 (37.8, 45.3)

Platelet count

120.0 ± 58.0

127.0 ± 60.0

113.0 ± 55.0

Lymphocyte count

1.22 (0.88, 1.58)

1.32 (0.93, 1.87)

1.13 (0.86, 1.44)

Neutrophil count

2.67 (1.85, 3.29)

2.94 (2.09, 3.32)

2.44 (1.65, 3.28)